Activating the patient's immune system to fight cancer

1Q 2019

9 May 2019

targovax

IMPORTANT NOTICE AND DISCLAIMER

This report contains certain forward-looking statements based on uncertainty, since they relate to events and depend on circumstances that will occur in future and which, by their nature, will have an impact on the results of operations and the financial condition of Targovax. Such forward-looking statements reflect the current views of Targovax and are based on the information currently available to the company. Targovax cannot give any assurance as to the correctness of such statements.

There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in these forward-looking statements. These factors include, among other things, risks or uncertainties associated with the success of future clinical trials; risks relating to personal injury or death in connection with clinical trials or following commercialization of the company's products, and liability in connection therewith; risks relating to the company's freedom to operate (competitors patents) in respect of the products it develops; risks of non-approval of patents not yet granted and the company's ability to adequately protect its intellectual property and know-how; risks relating to obtaining regulatory approval and other regulatory risks relating to the development and future commercialization of the company's products; risks that research and development will not yield new products that achieve commercial success; risks relating to the company's ability to successfully commercialize and gain market acceptance for Targovax's products; risks relating to the future development of the pricing environment and/or regulations for pharmaceutical products; risks relating to the company's ability to secure additional financing in the future, which may not be available on favorable terms or at all; risks relating to currency fluctuations; risks associated with technological development, growth management, general economic and business conditions; risks relating to the company's ability to retain key personnel; and risks relating to the impact of competition.

targovax

1

Intro & Highlights

2. ONCOS oncolytic virus program
3. TG mutant RAS vaccine program
4. 1Q 2019 Financials

targovax

TARGOVAX'S POSITION IN THE FUTURE CANCER THERAPY LANDSCAPE

Targovax focus



Immune activators

Oncolytic viruses, vaccines

Immune modulators

Checkpoint inhibitors



Surgery - Radio - Chemo



Immune boosters

CAR-Ts, TCRs

Targeted therapy

TKIs, PARPs, etc.



targovax

Two programs in clinical development, with an

ONCOLYTIC VIRUS LEAD PRODUCT CANDIDATE



ONCOS
Oncolytic virus

Lead product candidate

- Genetically armed **adenovirus**
- Triggers prodction of T-cells targeting the **patient's specific tumor**
- 4 ongoing trials



TG
Neoantigen vaccine

Pipeline product

- **Shared neoantigen**, therapeutic cancer vaccine
- Triggers prodction of T-cells targeting **mutant RAS cancers**
- 1 recently completed, 1 ongoing trial

Triggers patient-specific responses

No need for individualization

targovax

1Q HIGHLIGHTS

ONCOS

- Treated the first patient in the dose expansion cohort in the melanoma trial
- Completed enrollment of ONCOS-102 trial in mesothelioma (May)
- Finalized first development stage for new viruses, filed patents on three viruses

TG

- Signed collaboration agreement with Parker Institute for Cancer Immunotherapy and Cancer Research Institute

Corporate

- Received patent in the EU for TG in combination with chemotherapies, and a Notice of Allowance in the US for TG02 and TG03
- Granted Zelluna an FTO license to IP relating to mutant RAS T-cell receptor technology
- Raised NOK 74m in a Private Placement

2

ONCOS oncolytic virus program

2. TG mutant RAS vaccine program
3. 1Q 2019 Financials

targovax

PIPELINE OVERVIEW AND MILESTONES

Platform	Product candidate	Preclinical	Phase I	Phase II	Phase III	Next expected event
ONCOS oncolytic adenovirus	ONCOS-102	**Mesothelioma** Comb. w/ pemetrexed/cisplatin				**Around New Year** Randomized data
		Melanoma Comb. w/Keytruda				**1H 2019** ORR and immune data first cohort
		Peritoneal metastasis[1] Collab: Ludwig, CRI & AZ Comb. w/Imfinzi				*Update by collaborator, expected 2019*
		Prostate Collab: Sotio Comb. w/Dcvac				*Update by collaborator, expected 2019*
	Next-gen ONCOS	**3 viruses** undisclosed				**2H 2019** First pre-clinical data
TG neoantigen cancer vaccine	TG01	**Pancreatic cancer** Comb. w/gemcitabine				**1H 2019** 3-year survival data
	TG02	**Colorectal cancer** Proof-of-mechanism Comb. w/Keytruda				**1H 2019** Immune activation and mechanistic data (mono)
	TG02	**CPI synergy** TG + PD-1				**2H 2019** First pre-clinical data

[1] Patients with advanced peritoneal disease, who have failed prior standard chemotherapy and have histologically confirmed platinum-resistant or refractory epithelial ovarian or colorectal cancer

Ongoing collaborator sponsored trials

targovax

8

ONCOS-102 IS AN ONCOLYTIC ADENOVIRUS SEROTYPE 5 ARMED WITH A GM-CSF TRANSGENE

1

Selective replication
in cancer cells

2

Boosting the **immune activation**

3

Enhanced infection
of cancer cells



NEXT GENERATION ONCOS VIRUSES: DOUBLE TRANSGENES AND DISTINCT MODE OF ACTIONS

		Target tumors	Development status
	**ONCOS-211** *Counteract immune-suppressive tumor microenvironment*	○ "Cold" immune suppressive tumors	○ *In vitro* testing completed ○ *In vivo* testing ongoing
	**ONCOS-212** *Inhibition of tumor growth and vascularization*	○ Highly invasive or metabolic tumors	○ *In vitro* testing completed ○ First *in vivo* testing completed
	**ONCOS-214** *Enhanced cell killing properties*	○ Rapidly growing or large size tumors	○ *In vitro* testing completed ○ *In vivo* testing ongoing

targovax

3

TG mutant RAS vaccine program

4. 1Q 2019 Financials

targovax

TG CLINICAL PROGRAM OVERVIEW

Phase I & II - Pancreas
Monotherapy
>200 patients

→

Phase I/II Resected pancreas
Adjuvant, w/chemo
32 patients

→

Colorectal cancer
TG02 (+ Keytruda)
Phase I
up to 12 patients

- Mechanism of action trial
- 2nd generation TG vaccine
- 2 cohorts w/wo Keytruda
- Australia based

Metastatic Pancreas
TG01 + combination
Phase Ib/II

- US based trial, in collaboration with Parker Institute and CRI
- Combination with IO and chemotherapy to be determined

Resected Pancreas
TG01 + SoC
Phase II

- Pursuing academic partnership
- Externally sponsored and financed (mainly)
- EU or US based

Completed trials | Ongoing trials | Trial sponsored by partner (under planning)

targovax

TG01 IN RESECTED PANCREATIC CANCER

EFFICACY SIGNAL SEEN IN PHASE I/II TRIAL

Median overall survival, months



Median disease free survival, months



RAS-specific immune activation



TG01 is well-tolerated - improved dosing regimen in second cohort

Preliminary data

First cohort: 19 pts, Second cohort: 13 pts. Total 32 pts.
ESPAC4 trial for gemcitabine alone
DFS both cohorts: 16.1 months

TG01 resected pancreas cancer trial survival - first vs. second patient cohorts

3-YEAR SURVIVAL DATA IN MAY



 Preliminary data

4

1Q 2019 Financials

targovax

TARGOVAX HAS A SOUND FINANCIAL POSITION

Operations

Cash end of 1Q – and PP proceeds

172 / 20

NOK million USD million

Net cash flow - total 1Q

-46 / -5

NOK million USD million

Annual run rate - last four quarters

124 / 14

NOK million USD million

The share

Market Cap - at share price NOK ~6,5

410 / 48

NOK million USD million

Daily turnover - rolling 6 month avg.

2.8 / 0.3 / 0.7%

NOK million USD million

Analyst coverage

DNB, ABG Sundal Collier, Arctic, Redeye, Edison

targovax

PROFIT AND LOSS

NOK m	1Q18	2Q18	3Q18	4Q18	1Q19
Total revenue	**0**	**0**	**0**	**0**	**0**
External R&D expenses	-11	-14	-17	-21	-19
Payroll and related expenses	-16	-15	-12	-14	-14
Other operating expenses	-7	-7	-5	-7	-7
Total operating expenses	**-34**	**-37**	**-34**	**-42**	**-40**
Operating loss	-34	-37	-34	-42	-40
Net financial items	-1	-0	-1	1	-1
Loss before income tax	-35	-37	-35	-41	-41
Net change in cash	-32	-28	-27	-22	-46
Net cash EOP	**229**	**201**	**173**	**151**	**105**
Net cash including Private Placement					172

targovax

PIPELINE OVERVIEW AND MILESTONES

Platform	Product candidate	Preclinical	Phase I	Phase II	Phase III	Next expected event
ONCOS oncolytic adenovirus	ONCOS-102	**Mesothelioma** Comb. w/ pemetrexed/cisplatin				**Around New Year** Randomized data
		Melanoma Comb. w/Keytruda				**1H 2019** ORR and immune data first cohort
		Peritoneal metastasis[1] Collab: Ludwig, CRI & AZ Comb. w/Imfinzi				*Update by collaborator, expected 2019*
		Prostate Collab: Sotio Comb. w/Dcvac				*Update by collaborator, expected 2019*
	Next-gen ONCOS	**3 viruses** undisclosed				**2H 2019** First pre-clinical data
TG neoantigen cancer vaccine	TG01	**Pancreatic cancer** Comb. w/gemcitabine				**1H 2019** 3-year survival data
	TG02	**Colorectal cancer** Proof-of-mechanism Comb. w/Keytruda				**1H 2019** Immune activation and mechanistic data (mono)
	TG02	**CPI synergy** TG + PD-1				**2H 2019** First pre-clinical data

[1] Patients with advanced peritoneal disease, who have failed prior standard chemotherapy and have histologically confirmed platinum-resistant or refractory epithelial ovarian or colorectal cancer

Ongoing collaborator sponsored trials

targovax

18

Upcoming events

8-9 May	ChinaBio Partnering Forum, Shanghai, China
23 May	AX Exposure, live webcast
1-4 June	ASCO, Chicago, USA
3-6 June	Bio, Philadelphia, USA
3-7 June	Jefferies Healthcare Conference, NYC, USA
11 June	ABGSC Oncology seminar, Oslo, Norway

Upcoming milestones

1H 2019:	TG01- *3-year survival data*
1H 2019:	Melanoma - *ORR and immune data first cohort*
1H 2019:	TG02 - *Immune activation and mechanistic data (TG mono)*

Subsequent Offering

Open: 10 May 2019 at 09:00 CET

Close: 24 May 2019 at 16:30 CET

Subscription price: NOK 7.00

Subscription rights:
Registered holders of the Company's shares as appearing in the VPS as of 25 March 2019 who were not allocated shares in the Private Placement

targovax

ACTIVATING THE PATIENT'S IMMUNE SYSTEM TO FIGHT CANCER

ONCOS-102 lead product

One of the furthest developed oncolytic viruses

Strong single agent data

Several upcoming data points

TG mutRAS neoantigen vaccine

Clinical effect in resected pancreatic cancer

Immune activation against RAS mutations

Innovative pipeline

Next generation viruses in testing

Neoantigen vaccine platform with potential in TCR therapies